BPC-157 Non-Responder Profile: Who Doesn't Respond and Why

Is there a BPC-157 non-responder profile?

No. The human studies report how many patients improved, not which patient characteristics, doses, routes or product features predict response [3][4][1]. A 2026 systematic review searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov to June 1, 2026 and found three eligible human studies with 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low [1]. The reviewers concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [1].

What the human studies actually report

Knee pain: 17 charts, 16 patients reached

A retrospective chart review at one Florida clinic covered 17 patients treated in 2019 and 2020; 16 were reached by phone, most 6 months to 1 year after their injection [3]. Twelve received BPC-157 alone and four received it with thymosin beta-4 [3]. Of the 12 given BPC-157 alone, 11 (91.6%) reported significant improvement [3]. There was no control group, no validated tool for function, stiffness or quality of life, and results came from patients recalling how much the injection helped. No adverse events were noted [3].

Bladder pain: 12 women, all prior non-responders

Twelve women aged 39 to 76 with interstitial cystitis, none of whom had responded to pentosan polysulfate, received a single procedure injecting 10 mg of BPC-157 around the inflamed bladder wall [4]. Ten reported complete symptom resolution and 2 reported about 80% resolution; there was no placebo arm and scoring was patient-rated [4]. Every participant had failed an approved drug, not BPC-157.

Intravenous safety pilot: 2 adults

Two adults received 10 mg of BPC-157 intravenously on day 1 and 20 mg on day 2, with bloodwork and vital signs before and after [6]. No measurable change appeared in the tested heart, liver, kidney, thyroid or glucose markers and no side effects were reported [6]. This study measured safety markers, not symptom response, and 2 people cannot establish safety.

Ulcerative colitis: the only controlled trial FDA found

FDA's reviewers identified one randomized, placebo-controlled human trial in ulcerative colitis; it exists only as a meeting abstract and was never published as a full paper [2]. Per FDA, 53 people with mild to moderate ulcerative colitis were randomized to an 80 mg BPC-157 enema or placebo daily for 2 weeks. The abstract reported it was well tolerated with no difference in adverse events versus placebo, and FDA said it has too little detail to judge effectiveness [2].

What is known about how it works

FDA's July 2026 review states that BPC-157's molecular targets have not been identified, that its mechanisms 'remain poorly understood', and that dose-response relationships for the reported protective effects were not established [2]. The reported effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [2].

FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or skin use. After rectal enemas in two early studies, BPC-157 was mostly undetectable in blood, and FDA judged it appears not to be absorbed systemically by that route [2].

Factors people raise for non-response

Route of administration. FDA found no human study in which BPC-157 was given by mouth, by subcutaneous injection, as a nasal spray or on the skin [2]. Whether any of these routes delivers the peptide to a target tissue has not been measured in people [2].

Product identity and purity. Websites sell BPC-157 as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use', and those products are not FDA-approved drugs [2]. Compounded drugs are also not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [7]. For compounded BPC-157, FDA's stated concerns include possible immunogenicity for certain routes of administration and problems with peptide-related impurities and characterization of the active ingredient [8].

Other drugs. In rats, BPC-157 counteracted celecoxib-induced stomach, liver and brain lesions [9], and a review proposes it may act as an antidote to NSAID injury [10]. These are animal findings; they do not show whether NSAIDs change BPC-157's effects in people.

What is known about harms

FDA searched its adverse-event database through December 4, 2025 and found 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit, with no other detail; and widespread skin and gum darkening that recurred when the person was re-exposed to a BPC-157 plus TB-500 research product [2]. FDA said it cannot tell whether BPC-157 caused these [2].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information [2]. Animal signals noted by FDA include shortened clotting time (aPTT) in rats and prolonged aPTT in dogs in 28-day intramuscular studies, plus raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [2].

Dose and regulatory status

There is no FDA-approved dose because there is no approved product [2]. The doses used in the few human reports vary widely: rectal enema up to 2 mg/kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice for knee pain; 10 mg injected into the bladder wall once for interstitial cystitis; and 10 mg then 20 mg intravenously over two days in 2 healthy adults [2]. None of these is a recommended dose.

BPC-157 is not in any of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, so the category 1 policy under which FDA generally does not act against compounders does not cover it [11]. It was in category 2, the significant-safety-risk group, from September 2023 until April 22, 2026, and came off because the nominating groups withdrew; that removal was not a finding of safety [8][12]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation; the vote is nonbinding and BPC-157 is not on the list [13][12]. A draft HHS policy announced October 28, 2026 says HHS does not intend to take enforcement action against certain state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157 acetate if its conditions are met; the notice states it does not establish rights for any person and is not binding on HHS or the public [14][12]. In sport, WADA names BPC-157 in S0 and prohibits it at all times, and it remains named in the 2027 List [5][15].